Skip to main content

Table 4 Genotyping and allelic frequencies distribution of RARRES2 rs17173608 gene polymorphism between controls (non-MetS) and metabolic syndrome (MetS) group, and between T2DM and non-diabetics patients

From: The associations among RARRES2 rs17173608 gene polymorphism, serum chemerin, and non-traditional lipid profile in patients with metabolic syndrome

GenotypeNon-MetS group (n = 68) (%)MetS group (n = 100) (%)OR95% CIp valueNon-diabetics (84)T2DM (n = 84)Odds ratio95% CIp value
TT*38 (55.88%)36 (36.0%)RefRefRef28 (33.33%)51 (60.71%)RefRefRef
TG22 (32.36%)32 (32.0%)1.53540.75 to 3.120.235824 (28.57%)25 (29.76%)0.580.28 to 1.180.131
GG8 (11.8%)32 (32.0%)4.22221.7185 to 10.3740.001732 (38.1%)8 (9.52%)0.1370.055 to 0.3380.0001
RecessiveTT + TG60 (88.23%)68 (68%)3.52941.5101 to 8.2490.0036452 (61.9%)76 (90.47%)0.171.0.0730 to 0.40070.0001
GG8 (11.76%)32 (32%)32 (38.1%)8 (9.52%)
DominantTT38 (55.88%)36 (36%)0.44410.2367 to 0.8330.0014128 (33.33%)51 (60.71%)0.3230.172 to 0.6080.0005
TG + GG3064 (64%)56 (66.67%)33 (39.3%)
AdditiveTT38 (55.88%)36 (36%)4.22221.7185 to 10.3740.001728 (33.33%)51 (60.71%)0.1370.055 to 0.3380.0001
GG8 (11.76%)32 (32%)32 (38.1%)8 (9.52%)
AllelesT*98 (72.06)104 (52%)2.38061.4937 to 3.79410.000380 (47.62%)127 (7%5.6)0.2930.1845 to 0.4670.000
G38 (27.94)96 (48%)88 (52.38%)41 (24.4%)
  1. Data are represented as numbers and percentages. p < 0.05 is considered to be significant
  2. Numbers in bold indicated significant values
  3. OR odds ratio, CI confidence interval